GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

nipocalimab   Click here for help

GtoPdb Ligand ID: 13876

Synonyms: Imaavy® | M-281 | M281 | nipocalimab-aahu
Approved drug
nipocalimab is an approved drug
Compound class: Antibody
Comment: Nipocalimab (M281) is a fully human neonatal Fc receptor (FcRn; Fc gamma receptor and transporter FCGRT) targeting monoclonal antibody [2], that is designed to reduce circulating IgG antibody levels, with the focus on neutralising pathogenic autoantibodies in autoimmune diseases [3]. Its binding is pH insensitive, so it can bind IgG throughout the FcRn-mediated IgG recycling pathway, in the endosomal and extracellular compartments.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Akhtar M, Akhtar M, Farooqi HA, Maryam A, Muzammil A, Hanif U, Athar Z, Hassan SM, Khan Z. (2025)
Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and meta‑analysis.
Clin Neurol Neurosurg, 254: 108910 [Epub ahead of print]. [PMID:40288289]
2. Ling LE, Hillson JL, Tiessen RG, Bosje T, van Iersel MP, Nix DJ, Markowitz L, Cilfone NA, Duffner J, Streisand JB et al.. (2019)
M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.
Clin Pharmacol Ther, 105 (4): 1031-1039. [PMID:30402880]
3. Seth NP, Xu R, DuPrie M, Choudhury A, Sihapong S, Tyler S, Meador J, Avery W, Cochran E, Daly T et al.. (2025)
Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties.
MAbs, 17 (1): 2461191. [PMID:39936406]